RKDA Nasdaq Crude Petroleum & Natural Gas Financials FY2016βFY2025
Arcadia Biosciences, Inc. had $4.9M of revenue in fiscal 2025, down 3.7% on the year before. Over five years, revenue changed β9.6% a year on average.
Last close Β· Oct 23, 2026
$0.16
0.1%Hi! I read Arcadia Biosciences, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β3.7%
No. Sales fell 3.7% last year.
Does it make a profit?
β48.1%
No. It lost money last year.
Does profit turn into cash?
β96.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Arcadia Biosciences, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 6, 2026
Friday Β· in 11 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 13, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 14, 2026 | Q1 '26 | After the market closes | 8-K β |
| Mar 26, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 7, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 14, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 8, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Mar 20, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 12, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Arcadia Biosciences, Inc. had $4.9M of revenue in fiscal 2025, down 3.7% on the year before. Over five years, revenue changed β9.6% a year on average. Its operating margin was β51.5%, up 20.8Β pts: of every 100 in sales, about β51 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Arcadia Biosciences, Inc. lost $2.3M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$4.7M in fiscal 2025, β96.7% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Arcadia Biosciences, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $28.7M | $20.6M | $11.6M | $4.2M | $4.6M |
| Debt incl. finance leases | $0.0M | β | β | β | β |
| Debt / equity | 0.0x | β | β | β | β |
| Interest coverage | β1,776.3x | β | β | β | β |
| Current ratio | 7.0x | 6.0x | 4.2x | 3.6x | 3.1x |
| Quick ratio | 6.1x | 5.5x | 3.9x | 3.3x | 2.5x |
| Total assets | $43.9M | $28.9M | $19.7M | $13.5M | $6.5M |
| Total liabilities | $12.7M | $8.0M | $7.0M | $7.3M | $2.4M |
| Shareholders' equity | $31.1M | $21.0M | $12.8M | $6.2M | $4.1M |
| Net debt (β = net cash) | β$28.7M | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Arcadia Biosciences, Inc. passes 2 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 9 | 2 / 8 | 1 / 8 | 3 / 8 | 3 / 9 | 3 / 8 | 1 / 8 | 2 / 8 | 2 / 8 |
| Accruals ratio | β4.5% | β4.8% | 0.7% | β41.0% | 64.0% | 24.6% | β3.8% | 5.4% | 15.6% | 23.5% |
| Altman Z'' | β4.57 | β33.17 | β22.31 | β19.82 | β11.33 | β15.15 | β24.76 | β41.34 | β64.94 | β136.50 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $3.2M | $4.0M | $1.5M | $1.2M | $8.0M | $6.8M | $7.4M | $4.5M | $5.0M | $4.9M |
| Net interest income | β | β | β | β | β | β$0.0M | $0.3M | $0.7M | $0.8M | $0.2M |
| Gross profit | $2.3M | $3.7M | β | β | $2.8M | β$1.9M | $1.3M | $2.3M | $2.1M | $1.8M |
| Research and development | $8.7M | $7.4M | $6.1M | $7.1M | $8.0M | $3.9M | $1.5M | $0.1M | $0.1M | $0.0M |
| Operating income | β$18.6M | β$14.3M | β$16.9M | β$19.4M | β$12.8M | β$35.5M | β$14.0M | β$6.1M | β$3.6M | β$2.5M |
| Interest expense | $1.3M | $0.7M | β | $0.0M | $0.0M | $0.0M | β | β | β | β |
| Pretax income | β$19.6M | β$15.7M | β$13.5M | β$28.9M | β$6.2M | β$16.1M | β$10.8M | β$5.3M | β$4.3M | β$2.3M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | β$0.1M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$19.6M | β$15.7M | β$13.5M | β$28.8M | β$4.7M | β$14.7M | β$15.4M | β$14.0M | β$7.0M | β$2.3M |
| Net income to common | β$19.6M | β | β | β | β | β | β | β | β | β |
| Diluted EPS | β$8.85 | β$7.28 | β$3.58 | β$4.53 | β$0.47 | β$27.56 | β$25.65 | β$11.29 | β$5.17 | β$1.71 |
| Diluted shares | 0.00B | 0.00B | 0.00B | 0.01B | 0.01B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$17.1M | β$14.0M | β$13.6M | β$17.2M | β$30.2M | β$25.9M | β$14.0M | β$15.3M | β$9.6M | β$4.7M |
| Capital expenditure | $0.2M | $0.1M | $0.3M | $1.5M | $2.3M | $1.0M | $0.1M | $0.0M | $0.0M | $0.0M |
| Free cash flow | β$17.3M | β$14.0M | β$13.9M | β$18.7M | β$32.6M | β$26.9M | β$14.0M | β$15.3M | β$9.6M | β$4.7M |
| Depreciation and amortization | $0.3M | $0.3M | $0.2M | $0.2M | $0.6M | $0.9M | $0.4M | $0.1M | $0.1M | $0.0M |
| Stock-based compensation | $1.1M | $1.5M | $1.6M | $2.3M | $2.0M | $1.5M | $1.1M | $0.7M | $0.5M | $0.2M |
| Acquisitions | β | β | β | β | $0.5M | $4.3M | $0.0M | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $50.6M | $13.0M | $21.8M | $25.3M | $25.7M | $28.7M | $20.6M | $11.6M | $4.2M | $4.6M |
| Total debt | $25.1M | $0.0M | $0.0M | $0.1M | $3.2M | $0.0M | β | β | β | β |
| Current assets | $52.2M | $15.0M | $22.9M | $28.4M | $31.7M | $35.4M | $25.4M | $15.0M | $9.2M | $6.4M |
| Current liabilities | $3.1M | $3.5M | $3.1M | $5.7M | $6.3M | $5.0M | $4.2M | $3.6M | $2.6M | $2.1M |
| Inventory | $0.3M | $0.2M | $0.2M | $1.8M | $3.8M | $4.4M | $2.3M | $0.8M | $0.9M | $1.2M |
| Property and equipment, net | $0.5M | $0.3M | $0.4M | $1.8M | $3.5M | $2.3M | $0.7M | $0.1M | $0.0M | $0.0M |
| Goodwill | β | β | β | β | $0.4M | β | β | β | β | β |
| Intangible assets | β | β | β | β | $0.4M | $0.5M | $0.0M | $0.0M | $0.0M | $0.0M |
| Total assets | $56.6M | $16.6M | $24.0M | $32.6M | $47.3M | $43.9M | $28.9M | $19.7M | $13.5M | $6.5M |
| Total liabilities | $34.4M | $8.6M | $11.2M | $24.2M | $18.8M | $12.7M | $8.0M | $7.0M | $7.3M | $2.4M |
| Shareholders' equity | $22.2M | $8.0M | $12.8M | $7.7M | $27.7M | $31.1M | $21.0M | $12.8M | $6.2M | $4.1M |
| Margins | ||||||||||
| Gross margin | 71.9% | 93.0% | β | β | 35.3% | β28.4% | 17.8% | 51.2% | 41.3% | 36.2% |
| Operating margin | β584.1% | β355.6% | β1,152.3% | β1,657.9% | β159.0% | β524.0% | β188.8% | β137.0% | β72.3% | β51.5% |
| EBITDA margin | β574.5% | β348.6% | β1,141.8% | β1,641.3% | β151.2% | β510.3% | β182.9% | β134.5% | β71.2% | β50.8% |
| Net margin | β615.6% | β390.1% | β920.8% | β2,464.1% | β57.9% | β216.2% | β207.3% | β313.9% | β139.5% | β48.1% |
| FCF margin | β542.2% | β348.8% | β948.2% | β1,597.5% | β405.2% | β396.4% | β189.4% | β343.5% | β191.1% | β96.7% |
| Net interest share of revenue | β | β | β | β | β | β0.3% | 3.9% | 15.6% | 15.5% | 4.5% |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β190.3% | β1,165.5% | β | β | β | β |
| Return on capital employed | β34.8% | β109.7% | β80.4% | β72.1% | β31.1% | β91.4% | β56.7% | β37.9% | β33.3% | β55.7% |
| Return on equity | β88.4% | β104.0% | β129.5% | β280.8% | β26.3% | β49.8% | β59.0% | β82.5% | β73.8% | β45.1% |
| Return on assets | β34.7% | β42.9% | β66.4% | β101.8% | β11.6% | β32.1% | β42.2% | β57.5% | β42.4% | β23.3% |
| Return on tangible equity | β88.4% | β196.2% | β105.2% | β373.8% | β17.3% | β47.9% | β73.2% | β109.2% | β113.8% | β57.0% |
| Growth | ||||||||||
| Revenue growth | β | 26.3% | β63.6% | β20.2% | 587.3% | β15.6% | 9.4% | β40.0% | 13.3% | β3.7% |
| Share count change | β | β2.8% | 74.7% | 68.9% | 56.5% | β94.7% | 12.7% | 106.4% | 10.2% | 0.4% |
| Financial health | ||||||||||
| Debt / equity | 1.1x | 0.0x | 0.0x | 0.0x | 0.1x | 0.0x | β | β | β | β |
| Interest coverage | β14.1x | β19.2x | β | β3,876.2x | β271.9x | β1,776.3x | β | β | β | β |
| Current ratio | 16.7x | 4.3x | 7.5x | 5.0x | 5.0x | 7.0x | 6.0x | 4.2x | 3.6x | 3.1x |
| Quick ratio | 16.6x | 4.2x | 7.4x | 4.7x | 4.4x | 6.1x | 5.5x | 3.9x | 3.3x | 2.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 7.2% | 2.0% | 17.1% | 126.3% | 29.1% | 14.9% | 1.0% | 0.1% | 0.3% | 0.0% |
| Stock comp / revenue | 33.2% | 36.6% | 105.9% | 195.6% | 25.4% | 22.7% | 14.9% | 16.1% | 10.1% | 4.8% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 2.0 | 1.0 | 3.0 | 3.0 | 3.0 | 1.0 | 2.0 | 2.0 |
| Altman Z'' | β4.6 | β33.2 | β22.3 | β19.8 | β11.3 | β15.1 | β24.8 | β41.3 | β64.9 | β136.5 |
| Accruals ratio | β4.5% | β4.8% | 0.7% | β41.0% | 64.0% | 24.6% | β3.8% | 5.4% | 15.6% | 23.5% |
Source: SEC EDGAR XBRL filings (CIK 0001469443). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
